Valneva to Present at Jefferies 2017 Global Healthcare Conference in New York
Valneva, a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, today announced that Thomas Lingelbach, President... View Article
In Cell Art ’s co-founder invited to present at the SF Nano Summer School
In Cell Art, a biotechnology company specializing in nanocarrier technologies named Nanotaxi® for unlocking the promise of nucleic acids to... View Article
Lemer Pax: Posijet®, the history of an exemplary partnership
The latest version of Posijet®, a mobile unit for the preparation and injection of high-energy radiopharmaceuticals, has become the compact... View Article
OSE Immunotherapeutics: last news
OSE Immunotherapeutics present significant data on Selective Anti-SIRPa OSE-172 (Effi-DEM) OSE Immunotherapeutics announced that the Company presented in oral session significant data on... View Article
Portrait Olivier KITTEN, Affilogic
Olivier KITTEN, Founder & CEO Affilogic Atlanpole: What is the pitch of your business? Olivier Kitten: Affilogic is a... View Article
2017 BIO International Convention in San Diego
The 2017 Bio US will be held from June 19 to 22 in San Diego (USA). Atlanpole Biotherapies is preparing... View Article
Valneva Reports Best Financial Results in the Company’s History
Valneva Reports Best Financial Results in the Company’s History with its First Year of Positive EBITDA in 2016 The Company... View Article
Ose Immunotherapeutics presented New Data at American Association for Cancer Reasearch annual meeting
OSE Immunotherapeutics Presented New Data at AACR* Annual Meeting 2017 on OSE-172 (Effi-DEM), Company’s Checkpoint Inhibitor Blocking Suppressive Myeloid Cells... View Article
Bioeurope Spring: positive balance for Atlanpole Biotherapies members
BioEurope Spring took place from 20 to 22 March in Barcelona. It is the first partnering conference between the pharmaceutical... View Article
CESTI-IHU: Dendritic cells and IL-22BP: targets for an innovative immunotherapeutic strategy
Dendritic cells and IL-22BP: targets for an innovative immunotherapeutic strategy for the treatment of inflammatory diseases Within the 1064 INSERM... View Article